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Abstract 
Esophageal cancer, which consist of esophageal adenocarcinoma and esophageal squamous cell carcinoma, is one 
of the most common malignant tumors in the world, especially in the south of Iran and China. To find and investigate 
the biomarkers in the initiation, development and progression of esophageal cancer will help us predict the progno-
sis of esophageal cancer patients and improve the curative effect and survival rate. Here, we reviewed the potential 
biomarkers of esophageal cancer in three aspects: Immunohistochemical markers, blood-based markers, miRNA 
markers and Gene expression profiling. All these biomarkers provided promising therapeutic targets for the diagnosis, 
treatment, and prognosis of esophageal cancer.
© 2016 Tan et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made.
Background
Esophageal carcinoma (EC) is one of the most com-
mon malignant tumors in the world, with a wide distri-
bution in the south of Iran and China (Zali et al. 2011). 
It is a very deadly disease, with roughly 480,000 new 
patients every year, and it is the sixth leading cause of 
cancer deaths worldwide, the fifth in men and the eighth 
in women (Jemal et al. 2011). Around 80 % of the cases 
worldwide occur in less developed regions. In both 
sexes there are more than 20-fold differences in inci-
dence between the different regions of the world, with 
rates ranging from 0.8 per 100,000 in Western Africa 
to 17.0 per 100,000 in Eastern Asia in men, and 0.2 per 
100,000 in Micronesia/Polynesia to 7.8 per 100,000 in 
Eastern Africa in women.(Glbocan 2012: Estimated 
Cancer Incidence, Mortality and Prevalence worldwide 
in 2012. Available at http://globocan.iarc.fr). More than 
50  % of EC patients presented with distant metastasis 
when they were first diagnosed (Enzinger and Mayer 
2003). The most common type of EC is esophageal squa-
mous cell carcinoma (ESCC), with increasing morbid-
ity in Western countries. The other type is esophageal 
adenocarcinoma (EAC), which can occur in Barrett’s 
epithelial cells, as well as distal esophageal mucosa and 
cardia. The common symptoms of EC are dysphagia, 
chest pain, weight loss, pressure or breastbone burn feel, 
and cough. The risk factors for this malignancy include 
smoking, diet, gastroesophageal reflux disease (GERD), 
and human papillomavirus (HPV) (Salehi et  al. 2013). 
EC detection methods include esophagoscopy, positron 
emission tomography Raman spectrum, immunohis-
tochemistry (IHC), and biopsy. The last method is the 
diagnostic standard of esophageal cancer, and it is used 
to confirm the physical and imaging examination results 
(Cerfolio et  al. 2005). Obtaining accurate pre-treatment 
staging and then subsequently providing stage-appropri-
ate treatment is crucial in optimizing esophageal cancer 
outcomes. Currently, it is based in the cost-effective use 
of Endoscopy, Endoscopic ultrasound, CT and biopsy 
(Berry 2014).
The usual treatments for EC are surgery, radiotherapy, 
and chemotherapy, of which surgery is the most effec-
tive option. Despite the combination of modern surgical 
procedures, radiotherapy, and chemotherapy, local recur-
rence is common in patients in the advanced stages of the 
disease. The presence of regional lymph node metastasis 
in patients with tumor invasion and metastasis disquali-
fies them from surgery (Rice et  al. 2009). The survival 
rate is significantly low, and the average 5-year survival 
rate of one-third of patients is 35.45 % (Thompson et al. 
2008). These clinical facts clearly show that early detec-
tion is crucial to treatment. However, only 30 % of early 
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patients can be examined (Rice et al. 1998). As a result, 
studies on the molecular mechanism of the invasion and 
metastasis of EC are vital. Biomarkers can be detected 
using different detection methods, such as blood testing, 
IHC, molecular pathology, gene expression profile and 
biopsy. The biomarkers of EC are valuable in predicting 
the outcome and guiding treatments of the disease. Here, 
we review biomarkers in EC detection, diagnosis, treat-
ment, and prognosis.
Immunohistochemical biomarkers
IHC is the most widely applied pathological technique in 
determining the expression of tumor-associated proteins 
and in studying the prognostic and clinical relevance of 
biomarkers. To date, numerous investigations have dem-
onstrated that many immunohistochemical markers are 
potential diagnostic, prognostic, or predictive indicators 
of EC. The role of IHC in EC is important to elucidate 
pathways for epidermal growth, angiogenesis, and apop-
tosis. In this section, epidermal growth factor receptor 
(EGFR), p53, vascular endothelial growth factor (VEGF), 
and estrogen receptor (ER) will be described in detail.
EGFR is a transmembrane protein with intrinsic tyros-
ine kinase activity. It is associated with specific ligands, 
such as EGF and TGF-α, resulting in the homodimeri-
zation of EGFR or in heterodimerization with the other 
EGFR receptor family members. Elevated levels of EGFR 
or increased expression levels of the EGFR gene have 
been reported in a number of human cancers of epithe-
lial origin, including head and neck, thyroid, breast, and 
colon cancers. In a subset of these cancers, most nota-
bly breast, colorectal, and esophageal cancers, increased 
EGFR expression is associated with advanced disease, 
tumor metastases, and poor prognosis (Wang et  al. 
2013). A clinical study was carried out in the University 
of Texas MD Anderson Cancer Center (Wang et al. 2007), 
wherein the expression of EGFR in EAC was examined. 
The results revealed that EGFR expression in EAC is 
closely related to the pathological grade and lymph node 
metastasis, as well as poor disease-free and overall sur-
vival. However, it is independent of T staging. Sudo et al. 
(2007) investigated the presence of EGFR mutations in 19 
esophageal cancer cell lines and primary tumors by PCR 
and DNA sequencing targeting exons 18, 19, 20 and 21. 
They found three of the 19 cell lines had the same silent 
mutation at nucleotide 2607, a G-to-A substitution in 
exon 20. One of the 50 patients had an EGFR mutation in 
codon 719, resulting in an amino acid substitution from 
glycine to aspartic acid. These findings suggested that the 
expression of EGFR is associated with poor prognosis 
and can be used to predict patient outcome.
As a member of the EGFR family, epidermal growth 
factor receptor 2 (HER2) has become a therapeutic target 
for some tumors and has received much research atten-
tion. HER2, a transmembrane receptor tyrosine kinase 
family member, is involved in cell regulation, cell growth, 
survival, differentiation, and migration of important sub-
stances (Spector and Blackwell 2009). Its positive expres-
sion in breast cancer has been elucidated and applied to 
treatment and prognosis in clinical practice (Penault-
Llorca et al. 2009). The research scope of HER2 expres-
sion is various cancer types, such as gastric cancer and 
esophageal cancer, is also expanding. The relationship 
between ESCC and HER2 has been investigated, but a 
definite conclusion has not been reached (Lesnikova et al. 
2009). In a study involving 99 patients, the 7p12 (C-myc), 
8q24.12 (EGFR), and 20q13.2 genes were mostly ampli-
fied in severe dysplasia and adenocarcinoma, suggesting 
that the correlation between ESCC and HER2 is not exact 
(Rygiel et al. 2007). In addition, a prospective clinical trial 
is currently underway. The primary results suggested that 
the sensitivity and specificity for diagnosing severe dys-
plasia or adenocarcinoma are 88 and 100 %, respectively, 
by detecting HER2, c-myc, 20q13.2, and aneuploidy 
(Pacha et al. 2012). In a recent meta-analysis (Chan et al. 
2012), 1464 esophageal cancer patients in 14 studies were 
observed, with 322 (22  %) HER2-positive patients. The 
five-year mortality was significantly higher in the HER2-
positive group [odds ratio (OR) 1.43, 95 % CI 1.04–1.95, 
P = 0.03] than that in the controls. In addition, positive 
correlations between five-year mortality and HER2-pos-
itive squamous cell carcinoma (OR 2.88, 95  % CI 1.34–
6.17; P  =  0.006) and adenocarcinoma (OR 1.91, 95  % 
CI 1.15–3.17; P  =  0.01) were found. In the abovemen-
tioned studies, the survival rate of ESCC patients with 
HER2-positive expression decreased, possibly because of 
increased radiation resistance (Dreilich et  al. 2006) and 
the use of cisplatin-based chemotherapy (Akamatsu et al. 
2003).
A study on the expression of E-cadherin, α-catenin, 
and β-catenin in EAC revealed that the decrease in the 
expression of the three proteins is associated with a 
decrease in the survival of patients. The expression of 
E-cadherin in patients with neoadjuvant chemotherapy 
significantly decreased, with other traditional clinical and 
pathological features, including the depth of tumor inva-
sion, lymph node metastasis, and clinical stage.
In addition, p53 was detected through IHC, and it was 
found to play a supplementary role in the diagnosis of 
dysplasia, particularly low-grade dysplasia. Although it 
is not approved for clinical use, p53 may be particularly 
useful for providing another basis for the diagnosis of 
dysplasia (Kaye et  al. 2009). Patients with dysplasia are 
now advised to be examined using p53 IHC to improve 
diagnostic reproducibility (Fitzgerald et  al. 2014). Fur-
thermore, in some studies, EC patients with abnormal 
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p53 IHC show three to eight times more rapid progres-
sion of this disease, indicating that it can also be used as 
a predictor of disease progression (Sikkema et al. 2009). 
Combined with other factors, p53 can be considered a 
risk factor for disease progression. For example, in the 
diagnosis of low-grade dysplasia, three pathological sci-
entists agreed that the expression of p53 protein immu-
nohistochemical abnormalities may be considered a 
major risk of disease progression (Skacel et al. 2002).
VEGF is a potent source of angiogenesis, and it is 
responsible for the development and maintenance of 
a vascular network that promotes tumor growth and 
metastasis for a wide range of human tumors and human 
cell lines (Weston et al. 2001). In clinical specimens, the 
expression of VEGF-C in EC tissues was significantly 
higher than that in noncancerous tissues (P  =  0.026). 
Other studies have confirmed that the positive expres-
sion of VEGF-C may be closely related to the progres-
sion of the disease (Sikkema et al. 2009; Skacel et al. 2002; 
Weston et al. 2001; Bird-Lieberman et al. 2012).
In a recent study (Zuguchi et  al. 2012), ER types ERa 
and ERb were detected in 90 cases of ESCC. ERa and ERb 
were detected in the nuclei of ESCC (41.1 and 97.8  %, 
respectively). Collecting relevant evidence may prove 
that ERb can be used as an indicator of a treatment or 
prognosis in the future.
In addition, MEKK3/MAP3K3 overexpression is 
important in the development of cancer (Kumar et  al. 
2007). Glickman et  al. (2001) analyzed a series of EACs 
and squamous cell carcinoma and demonstrated p53 
expression in 100 % of ESCC with no expression identi-
fied in EAC. DiMaio et al. (2012) examined the expression 
of eight immunohistochemical markers, including the 
novel markers SOX2 (sex determining region Y-box  2) 
and AGR2 (Anterior gradient 2), in a large series of EAC 
and ESCC to determine the optimal panel of immunohis-
tochemical markers for distinguishing these tumors. In 
clinical and scientific studies, the molecular mechanism 
of many diseases has been revealed by IHC and molecu-
lar pathology, which is related to the prognosis of many 
diseases.
Blood‑based biomarkers
In the early stages of carcinogenesis, the antigen immune 
response is believed to occur during cancer immune 
surveillance, in which the antigen is recognized by the 
immune system and destroys the invading pathogen and 
host cell of the cancer (Finn 2005). Antibodies against 
tumor-associated antigen (TAA), which is present in the 
serum of patients with various types of cancers, can be 
used as a biomarker for early diagnosis of EC. These anti-
bodies are complex and are not yet fully understood in 
the theory of cancer generation (Zaenker and ZimanMR 
2013). Many researchers are now interested in TAA with 
a higher level of stability and persistence in serum sam-
ples, especially in normal human and tumor patients 
(Anderson and LaBaer 2005). Numerous studies have 
indicated that TAAs in the blood circulation of tumor 
patients can be detectable several years earlier than the 
positive imaging findings, so they can be used as novel 
screening markers (Tan et  al. 2009). Thus, TAAs pro-
duced by autoantibodies can be biomarkers for the early 
detection of malignant transformation criteria for pre-
clinical studies, which can be used as a biomarker for 
early detection (Tan and Zhang 2008). We will review 
some of the biomarkers in the serum or plasma that have 
been recently validated in several experiments.
Anti-p53 induced by mutant p53 protein in serum is 
one of the most frequently tested antibodies. With the 
development of molecular biotechnology, a large num-
ber of studies on the potential diagnostic value of serum 
p53 antibody for esophageal cancer have been published, 
reporting varied results. Anti-p53 is popular in various 
studies in China, Japan, USA, Germany, India, and other 
countries. The cases in these studies were mostly ESCC, 
and only two of them involved EAC (Kilic et  al. 2008). 
Most antibodies have good specificity (specificity 98.3 %), 
but the average sensitivity is 26.7 %. Zhang et al. (2012) 
summarized the potential diagnostic value of serum p53 
antibody in EC. Based on the current evidence, they con-
cluded that serum p53 antibody has a potential diagnos-
tic value for EC. However, its discrimination power is not 
perfect because of its low sensitivity. These results sug-
gested that s-p53-antibody may be useful for monitoring 
residual tumor cells and for aiding in the selection of can-
didates for less invasive treatment procedures because 
of the high specificity of s-p53-antibody. Further studies 
may be needed to identify patterns of multiple biomark-
ers to increase the power of EC detection. A number of 
studies have evaluated (Xu et al. 2014) the stages at which 
diagnosis using autoantibodies and autoantibody panels 
of esophagus-specific cancer are valuable.
Shimada et  al. (2005) found that four antibod-
ies (i.e., SURF1, HOOK2, LOC146223, and AGEN-
COURT_7565913) are highly specific for esophageal 
cancer, compared with breast cancer, gastric cancer, colo-
rectal cancer. Kilic et al. (2008) used microarrays to iden-
tify the combination of Fas ligand and anti-NY-ESO-1, 
and the diagnostic sensitivity and specificity obtained for 
the detection of EAC were 88.9 and 100 %, respectively. 
Autoantibody markers and a combination of antibodies 
and other proteins can be detected using a combination 
of antibody markers and conventional tumor markers, 
such as CEA, CYFRA211, or SCC-Ag. For example, Dong 
et  al. (2010) found that the positive detection rate of 
markers for a combination of CEA, SCC, CYFRA211, 
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and CDC25B-Abs (64.2  %) is significantly higher than 
that for a combination of CEA, CYFRA211, and SCC-Ag 
in patients with ESCC (41.0 %). In a clinical trial, Bagaria 
B and colleagues determined the clinical serum levels of 
CEA and CA199, both individually and in combination, 
for the diagnosis of healthy subjects and EC. Compared 
with the control group, serum CEA levels were signifi-
cantly higher in cancer patients. The sensitivity of CEA 
in EC was 28  %. The sensitivity of CA19-9 was 18  %, 
whereas the sensitivity of CEA/CA19-9 combined in EC 
was 42 %. These results revealed that combined CEA and 
CA199 analysis indicate an increase in diagnostic sensi-
tivity in EC (Bagaria et al. 2013).
mRNA‑based biomarkers
MicroRNA (miRNA) is a group of evolutionary con-
served single chain non-coding RNAs that can participate 
in physiological processes, such as cell differentiation, 
proliferation, metabolism, and apoptosis. Some miRNAs 
play an important role in the tumor gene or tumor sup-
pressor gene in the development of tumors. Circulating 
plasma and serum miRNAs are potential markers for 
noninvasive cancer diagnosis, which can be used in the 
diagnosis, prognosis, and targeted therapy of EC.
Increasing evidence suggested that miR-129 has the 
potential to become a companion diagnostic biomarker 
along with clinical histopathological diagnosis. In addi-
tion, miR-129 expression is reduced in patients with 
endometrial cancer, resulting in changes in SOX4 (sex 
determining region Y-box  4) in the body (Huang et  al. 
2009). Similar results were also found in the study of 
esophageal cancer and liver cancer (Kang et  al. 2013). 
SOX4 is a transcription factor closely related to several 
critical pathways in the process of tumorigenesis, such 
as TGF-β (transforming growth factor-beta), Notch, 
and hedgehog signaling. It may play an important role 
in tumor metastasis and progression (Vervoort et  al. 
2013). Therefore, miR-129 may be a promising diagnostic 
marker for EC.
In other studies (Zhang et  al. 2014), researchers have 
described the role of miR-200 in tumor progression, inva-
sion, metastasis, and drug resistance. Surprisingly, miR-
200b inhibits EC cell invasion in vivo without altering the 
expression of the two surrogate markers of the epithelial–
mesenchymal transition (EMT), namely, E-cadherin and 
vimentin. However, whether miR-200-zeb1/2-e-cadherin 
cascade regulation, as a primary regulator of the EMT, is 
associated with the regulation of ESCC invasion remains 
unclear. The methylation of the E-cadherin gene is regu-
lated by the miR-200b-zeb1/2 axis, which indicated that 
the e-cadherin-independent mechanism can regulate the 
biological function of miR-200b in ESCC. Moreover, they 
also found that miR-200b inhibits the integrin β1-AKT 
pathway via targeting kindlin-2 to reduce the invasion 
of ESCC. In two independent samples of EC (n = 20 and 
n  =  53, respectively), the expression of kindlin-2 was 
positively correlated with the activation state of the integ-
rin signaling pathway and the PI3 K-AKT signaling path-
way (P  <  0.01). These findings suggested that kindlin-2 
integrin β1-AKT can function as a regulatory master 
in the tumor suppressor function of miR-200b in ESCC 
patients. In addition to our study of ESCC (Zhang et al. 
2014), only one other clinical study reported the abnor-
mal expression of miR-200 in EC, and the results showed 
a decrease in miR-200 expression in Barrett’s esophagus 
and EAC patients (Smith et al. 2011). However, informa-
tion on miR-200 in ESCC remains unclear, which may be 
because ESCC is a malignant tumor with high frequency 
of local invasion and metastasis.
Various studies reported that other miRNAs are 
involved in the onset, development and progression of 
EC. Uemura and Kondo (2014) found that predictive 
markers for individualization of multimodality treat-
ments are urgently needed in esophageal cancer and 
showed that miR-31 expression was markedly reduced 
in patients with poor pathological response to neoadju-
vant CRT, whereas the expression of the miR-31-regu-
lated DNA repair genes significantly increased. Luthra 
et  al. (2008) showed that the expression of miR-196a is 
negatively related to A1 (ANX). ANXA1, which can 
mediate cell apoptosis and inhibit cell proliferation, is 
weakly expressed in EC tissues. Another study (Hiyoshi 
et al. 2009) found that miR-21 is highly expressed in EC 
cell lines, and it is abundantly expressed in patients with 
lymph node metastasis and venous invasion. Kan et  al. 
(2009) reported that miR-106b-25 can inhibit the expres-
sion of target genes p21 and Bim and promote the trans-
formation from Barrett to EAC. Matsushima et al. (2011) 
found that miR-205 can inhibit the expression of ZEB 
(Zinc finger E-box bindinghomeobox),thereby blocking 
the EMT (epithelial-to-mesenchymal transition), as well 
as the invasion and metastasis of ESCC. Ohta et al. (2008) 
reported that the tumor invasion in the low GNG7 [gua-
nine nucleotide binding protein (G protein), gamma 7] 
expression group is higher than that in the high expres-
sion group; moreover, the survival rate is low, and GNG7 
expression is regulated by miR-328. The low expression 
of miR-375 in patients with EAC is closely related to poor 
prognosis (Mathe et  al. 2009). Furthermore, miR-27a 
may affect the multidrug resistance of EC; low miR-27a 
can significantly reduce the expression of P-glycoprotein 
and Bcl-2, inhibit the transcription of the multiple drug 
resistance-1 gene, and increase Bax expression (Zhang 
et al. 2010). Therefore, further research on the biological 
function of miRNA may provide a novel direction for the 
diagnosis and treatment of EC.
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In addition to miRNA, long noncoding RNAs (lncR-
NAs), another type of RNA molecule, are steadily becom-
ing the next frontier of cancer research. Recent findings 
confirmed that lncRNA is a key regulator of tumor devel-
opment and progression in the esophagus. LncRNA can 
be easily and rapidly extracted from serum and tissue, as 
well as in the gastric juice in EC patients. It is expected 
to be a useful biomarker and therapeutic tool in clinical 
practice.
Gene expression profiling biomarkers
Currently, gene expression microarray which gener-
ates quantitative expression data for thousands of genes, 
has been considered as a powerful tool for understand-
ing the biological characteristics of cancers (Quacken-
bush 2006). In a study involving 47 patients who had a 
locally advanced esophageal adenocarcinoma (AC) and 
had undergone neoadjuvant chemotherapy with cispl-
atin, leucovorin and 5-fluorouracil, followed by resec-
tion. Microarray analysis was performed to discover the 
differential expression gene profiles. It was found that the 
gene encoding the ephrin B3 receptor showed the most 
prominent differential expression between responders 
and non-responders, as well as these results by immu-
nohistochemistry (Schauer et  al. 2010). Additionally, in 
order to identify expression patterns predictive for cis-
platin-based neoadjuvant chemotherapy, Motoori et  al. 
(2010) analysed comprehensive gene expression profil-
ing of pretreatment biopsy tissues from 25 patients with 
esophageal squamous cell carcinoma (SCC). Their system 
consisted of 199 most informative genes and had the pre-
diction accuracy of 82 %. Duong et al. (2007) performed 
microarray analysis for 46 esophageal cancer patients, 
that is, 21 SCC and 25 AC patients for whom neoadju-
vant CRT had been recommended. Their study was based 
on two-color competitive hybridization to a cDNA array 
printed at the Peter MacCallum Cancer Centre Micro-
array Core Facility and identified a 32-gene classifier 
that could be used to predict a response to neoadjuvant 
CRT in SCCs, whereas a negative predictive profile was 
observed for AC patients. These examples suggest that 
gene expression profiling is a powerful tool to identify 
gene sets for selection of optimal and personalized ther-
apy for patients with esophageal cancer.
Conclusion
Cancer biomarkers have provided some promising thera-
peutic targets for the diagnosis, treatment, and prognosis 
of EC. They are needed to develop a treatment strategy 
for EC, which can be integrated with diverse clinical 
characteristics. The current study has shed light on the 
limitations of EC biomarkers, and further technologi-
cal advances can be anticipated. For example, analytical 
methods, such as blood test, IHC, molecular pathology, 
gene expression profile and biopsy, will be helpful in 
finding the appropriate antibodies to discover and verify 
more biomarker candidates. To obtain research data, in 
addition to improving the performance of the biomark-
ers, interdisciplinary cooperation is necessary. These 
results can benefit patients with EC, as well as other can-
cer patients.
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